| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Division of Cancer Neurology (A.D.N., A.S.C., L.G.E., B.L., J.D., S.K., P.Y.W.), Department of Neurology, Brigham and Women's Hospital and Center For Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School; Brigham and Women's Hospital Department of Radiology and Harvard Medical School (G.S.Y., K.S., R.K., G.L.R.); and Massachusetts General Hospital Biostatistics Center (A.M.), Boston.
Address correspondence and reprint requests to Dr Norden, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, SW430B, 44 Binney St., Boston, MA 02115 anorden{at}partners.org
Background: Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, may have activity in recurrent malignant gliomas. At recurrence some patients appear to develop nonenhancing infiltrating disease rather than enhancing tumor.
Methods: We retrospectively reviewed 55 consecutive patients with recurrent malignant gliomas who received bevacizumab and chemotherapy to determine efficacy, toxicity, and patterns of recurrence. Using a blinded, standardized imaging review and quantitative volumetric analysis, the recurrence patterns of patients treated with bevacizumab were compared to recurrence patterns of 19 patients treated with chemotherapy alone.
Results: A total of 2.3% of patients had a complete response, 31.8% partial response, 29.5% minimal response, and 29.5% had stable disease. Median time to radiographic progression was 19.3 weeks. Six-month progression-free survival (PFS) was 42% for patients with glioblastoma and 32% for patients with anaplastic glioma. In 23 patients who progressed on their initial therapy, bevacizumab was continued and the concurrent chemotherapy agent changed. In no case did the change produce a radiographic response, but two patients had prolonged PFS of 20 and 31 weeks. Recurrence pattern analysis identified a significant increase in the volume of infiltrative tumor relative to enhancing tumor in bevacizumab responders.
Conclusions: Combination therapy with bevacizumab and chemotherapy is well-tolerated and active against recurrent malignant gliomas. At recurrence, continuing bevacizumab and changing the chemotherapy agent provided long-term disease control only in a small subset of patients. Bevacizumab may alter the recurrence pattern of malignant gliomas by suppressing enhancing tumor recurrence more effectively than it suppresses nonenhancing, infiltrative tumor growth.
Abbreviations: AA = anaplastic astrocytoma; AG = anaplastic glioma; CR = complete response; GBM = glioblastoma; EIAED = enzyme-inducing antiepileptic drug; FLAIR = fluid-attenuated inversion recovery; KPS = Karnofsky Performance Status; MR = minimal response; PFS = progression-free survival; PR = partial response; rFPR = relative FLAIR progression ratio; rNTR = relative nonenhancing tumor ratio; T1W = T1-weighted; VEGF = vascular endothelial growth factor.
*These authors contributed equally to this work.
Supported by the Amos E. Wasgatt Brain Tumor Research Fund.
Disclosure: P.Y. Wen receives research support from Genentech, Inc. The other authors report no conflicts of interest.
Received July 2, 2007. Accepted in final form September 18, 2007.
This article has been cited by other articles:
|
|
 |
|
  New Brain Tumor Therapies, New Recurrence Patterns Journal Watch Neurology, May 6, 2008; 2008(506): 1 - 1. [Full Text]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
